Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...

In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American ...

Optinose (NASDAQ: OPTN) has announced preliminary unaudited net product revenue of $22.4 million for the fourth quarter of ...

by ICS-subtype consisting of a ‘fluticasone-group’ (fluticasone propionate or fluticasone furoate) and an ‘MBBC-group’ (mometasone furoate, beclomethasone, budesonide or ciclesonide). The outcome was ...

Optinose, Inc. (OPTN), a pharmaceutical company focused on ear, nose and throat or ENT and allergy, announced Wednesday preliminary ...

announced today a preliminary unaudited net product revenue of $22.4 million for XHANCE (fluticasone propionate) for the fourth quarter ending December 31, 2024. The company, currently trading ...

Jan. 15, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary ...

Fluticasone Furoate {(FF), 110 micrograms once daily}, and Fluticasone Propionate {(FP), 200 micrograms once daily} in AR. Nasal symptoms were evaluated using a Visual Analog Scale of 1 to 10, Nasal ...

Please provide your email address to receive an email when new articles are posted on . The ACG developed 19 recommendations related to the diagnosis and management of eosinophilic esophagitis ...